Project Grant R01AA032555
- This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) provides $440,566 to Yale University to advance the treatment of alcohol-associated liver disease (ALD). The primary objective is to uncover therapeutic targets and develop effective ALD treatments, with a focus on the methyltransferase-like (METTL) protein family, notably METTL7A, which is highly expressed in ALD patients. The research utilizes cutting-edge technology...
- This federal Project Grant award of $701,051 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The grant supports research to investigate the phenotypes and functions of distinct neutrophil populations in patients with severe alcohol-associated hepatitis (AH). Key objectives include: 1) Characterizing the transcriptomic profiles and functional roles of neutrophil subsets in AH using single-cell RNA sequencing; 2)...
- This federal Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs), supports research to determine the molecular mechanism by which the neutrophilic NCF1 gene and its downstream target miR-223 impact the pathogenesis of alcohol-associated liver disease (ALD). The $249,000 project, awarded to the Trustees of Indiana University, will investigate how neutrophils drive disease severity and mediate liver injury in ALD through the...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $404,250 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Tennessee Health Science Center. The grant, awarded on September 23, 2025 with an ultimate completion date of August 31, 2027, supports research to explore the role of margaric acid in alcohol-associated liver diseases (AALD). The project aims to determine if margaric acid supplementation can attenuate alcohol-induced gut and liver...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,376,398 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to develop a humanized mouse model to study alcohol-associated hepatitis (AAH). The project aims to create a fully humanized mouse liver system by engrafting human hepatocytes and non-parenchymal cells to better understand the complex cell interactions that drive key features of AAH, a leading cause of liver-related deaths...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $550,417 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Texas at Austin. The grant, effective September 1, 2025 through May 31, 2030, supports research to investigate how heavy alcohol exposure in aging individuals leads to impaired microglia function, neurodegeneration, and cognitive deficits. The study aims to determine whether dysregulated neuroimmune and microglia responses are...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...
- This federal Project Grant award of $3,182,397.00 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to the University of California, San Diego (UCSD). The grant aims to characterize the role of host gut proteases, particularly cathepsin B, and the immune response in alcohol-associated liver disease (ALD) in both a human cohort and a mouse model. The research seeks to determine how alcohol-mediated induction of...
- The federal Project Grant award titled "Role of Functional Iron Deficiency in Alcohol-Associated Liver Disease" is funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The $390,480 award, effective from September 10, 2025 to August 31, 2027, will support research at Emory University to investigate the molecular mechanisms underlying alcohol-associated mitochondrial dysfunction and its role in the progression of...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $253,383 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to explore the role of the hepatocyte inflammasome in alcoholic liver disease (ALD). This research aims to investigate the liver-specific effects of the inflammasome, a key mediator of inflammation, in hepatocytes - the predominant liver cell type and a driver of ALD pathophysiology. The project will use mouse models to evaluate...
This Project Grant award of $639,177.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, will support research to investigate the role of hepatic FOXA3 in the development and progression of alcohol-associated liver disease (ALD). The University of Arizona will conduct this research project to gain a better understanding of the mechanisms underlying the pathogenesis of ALD, which is the most prevalent type of chronic liver disease worldwide. The project aims to use gain- and loss-of-function approaches and state-of-the-art techniques to determine if hepatic FOXA3 is a key player in the pathogenesis of ALD. The award has an ultimate completion date of June 30, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $639.2k | 9/12/25 |